Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
341
datasets available to search
ShareScore release 0.9.0
Dataset results
341 results for “pharmacists”
Pharmacist Led Intervention to Improve Medication Use in Older In-patients Living With Frailty: the Drug Burden Index
ClinicalTrials.gov study NCT03698487. IPD Sharing: YES. Countries: 1. Publications: 2.
The Effect of a Pharmacist Home Visit on Drug-related Problems Post-discharge.
ClinicalTrials.gov study NCT01897870. IPD Sharing: Not stated. Countries: 1. Publications: 3.
Pharmacists Intervention to Improve Hypertension Management in Primary Care
ClinicalTrials.gov study NCT03274531. IPD Sharing: NO. Countries: 1. Publications: 1.
Impact of Hospital Pharmacist on Drug Management in Patients With Bronchopulmonary Cancer
ClinicalTrials.gov study NCT06469957. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Effect of Community Pharmacist Intervention on Adherence to Long-Term Medications
ClinicalTrials.gov study NCT02604901. IPD Sharing: Not stated. Countries: 1. Publications: 10.
Pharmacist Intervention for Glycemic Control in The Community
ClinicalTrials.gov study NCT01335763. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Clinical Pharmacist-led Appropriate Acid Suppression Therapy Stewardship Program
ClinicalTrials.gov study NCT05113667. IPD Sharing: NO. Countries: 1. Publications: 1.
Impact of Pharmacist-led Educational Intervention on Pneumococcal Vaccination Rates in Cancer Patients
ClinicalTrials.gov study NCT05229081. IPD Sharing: YES. Countries: 1. Publications: 5.
Impact of Clinical Pharmacist on the Quality and Cost of the Therapeutic Management of Patients in Two Medical Services of a Teaching Hospital
ClinicalTrials.gov study NCT02887001. IPD Sharing: Not stated. Countries: 0. Publications: 1.
Implementation of a Pharmacist-Driven Antipsychotic Deprescribing Initiative in the PACE Setting: A Pilot Study
ClinicalTrials.gov study NCT04288193. IPD Sharing: UNDECIDED. Countries: 1. Publications: 4.
Health Promoters and Pharmacists in Diabetes Team Management
ClinicalTrials.gov study NCT01498159. IPD Sharing: Not stated. Countries: 1. Publications: 5.
Leveraging Community Pharmacists to Optimize Smoking Cessation Services for Rural Smokers in Appalachia
ClinicalTrials.gov study NCT05660525. IPD Sharing: NO. Countries: 1. Publications: 1.
The Impact of Pharmacist-led Mobile Application on Adherence in Chronic Kidney Disease Patients
ClinicalTrials.gov study NCT05168449. IPD Sharing: NO. Countries: 1. Publications: 1.
Data from: Evaluation of the first pharmacist-administered vaccinations in Western Australia: a mixed-methods study
Open the record for dataset details and reuse information.
Data from: Characterizing the interaction between physicians, pharmacists and pharmaceutical representatives in a middle-income country: a qualitative study
Background: Studies around the world have shown that interactions between pharmaceutical companies, pharmacists and physicians have a great influence on prescribing and drug dispensing practices. In middle-income countries, the nature and extent of these interactions have not been well researched. Our objectives were to qualitatively explore the nature of the interactions between pharmaceutical companies, physicians and pharmacists, their impact on drug prescription and dispensing practices in Lebanon. Methods and Findings: We used grounded theory approach as well as the known sponsor, purposive, and snowballing sampling strategies to identify interviewees from the three respective groups: physicians, pharmacists, and pharmaceutical representatives. We conducted semi-structured and analyzed transcripts thematically. 6 pharmaceutical representatives, 13 physicians and 13 pharmacists participated in the study. The following themes emerged: purpose and driver for the interactions, nature of the interactions, incentives, impact on prescription practices, ethical considerations, and suggestions for managing the interactions. The main purposes for the interaction were educational, promotional, and monitoring prescription practices and dispensing, while the main drivers for these interactions were market potential and neighborhood socio-economic status. Physicians, pharmacists and pharmaceutical representatives who engage in these interactions benefit from a variety of incentives, some of which were characterized as unethical. It appears that pharmaceutical companies give prominence to selected physicians within their communities. Although members of the three interviewed groups refer to some of the interactions as being problematic, they described a culture of acceptance of gift giving. We developed a framework that depicts the prevailing politico-cultural environment, the interactions between the three professional groups, and their impact on drug prescription. Underreporting is the main limitation of this study. Conclusion: Interactions between physicians, pharmacists and pharmaceutical representatives are frequent. Although these interactions can be beneficial, they still have a substantial effect on drug prescription and dispensing practices. Hence, the need for new policies that regulate these interactions and penalize any misconduct.
The effects of multifactorial pharmacist-led intervention protocol on medication optimisation and adherence among patients with type 2 diabetes
Open the record for dataset details and reuse information.
The survey data of patients, prescribers, and pharmacists' feedback on ePrescription systems security and privacy
<p><b>Objective: </b>To evaluate the attitudes of the parties (i.e. patients, prescribers, and pharmacists) involved in the ePrescription systems toward the new features and measure the potential benefits of introducing the use of blockchain and machine learning (ML) to strengthen the in-place methods for safely prescribing and dispensing<span><span> medication. </span></span></p> <p><b>Methods: </b>The survey contains questions about the features introduced in the proposed approach of using blockcahin and ML in the ePrescription system to evaluate the security, privacy, reliability, and availability of the ePrescription information in the system.</p> <p>The study population is comprised of 284 respondents in the patient group, 39 respondents in the pharmacist group, and 27 respondents in the prescriber group, all of whom met the inclusion criteria. The response rate was 80% (226/284) in the patient group, 87% (34/39) in the pharmacist group, and 96% (26/27) in the prescriber group. We removed the responses of participants who did not complete the surevy questions.</p> <p><b>Conclusion: </b>Our survey showed that a vast majority of respondents in all groups had positive attitudes towards using blockchain and ML algorithms to safely prescribe medications. However, a need for minor improvements regarding the proposed features was identified, and a post-implementation user study is needed to evaluate the proposed ePrescription system in depth.</p>
Figure 6 from: Balkanski S, Simeonova J, Gitev I, Getov I (2019) Evaluation of the current status of the value-added pharmacy services and pharmacists' attitude in Bulgaria. Pharmacia 66(2): 79-83. https://doi.org/10.3897/pharmacia.66.e36530
Figure 6 How patients would rate VAPS – community pharmacists` opinion according to their professional experience (%).
Figure 5 from: Balkanski S, Simeonova J, Gitev I, Getov I (2019) Evaluation of the current status of the value-added pharmacy services and pharmacists' attitude in Bulgaria. Pharmacia 66(2): 79-83. https://doi.org/10.3897/pharmacia.66.e36530
Figure 5 Distribution of pharmacies by gender and their attitudes to participate in future practical training in different medical manipulations, vaccination and first aid training (%).
Supplementary material 4 from: Giua C, Mucherino S, Floris N, Keber E, Makoul G, Scala D, Orlando V, Menditto E (2022) Adaptation of communication assessment tool for community pharmacists in medication adherence and minor diseases management. Pharmacia 69(2): 571-578. https://doi.org/10.3897/pharmacia.69.e80742
Confirmatory factor analysis
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.